J0013 is the permanent HCPCS Level II code for esketamine nasal spray (Spravato), billed at one unit per 1 mg administered.
CMS introduced J0013 on January 1, 2026, replacing temporary code S0013 with the same descriptor, “Esketamine, nasal spray, 1 mg.”
J0013 reports only the Spravato drug product, while office visits, supervision, and the required two-hour REMS observation are billed separately using the appropriate service codes, including G2082 or G2083.
Medicare, commercial insurers, and Medicaid apply different reimbursement rules, making accurate unit reporting and payer-specific billing essential.
This guide covers J0013 billing, the S0013 transition, unit calculations, G2082 and G2083, payer requirements, documentation, and claim denial prevention.
Why Did S0013 Change to J0013 in 2026?
S0013 was discontinued and replaced by J0013 on January 1, 2026, under the CMS January 2026 HCPCS Level II update. CMS posted the code files on November 24, 2025.
Here is the short version of the change:
- Before January 1, 2026: esketamine nasal spray was reported with S0013.
- On and after January 1, 2026: esketamine nasal spray is reported with J0013.
S0013 was a temporary S-code. S-codes are kept for commercial payers and Medicaid programs, and they sit outside the permanent national HCPCS structure. CMS retired S0013 and moved esketamine into a permanent J-code. The descriptor stayed the same: “Esketamine, nasal spray, 1 mg.” Only the code changed.
This affects every payer that used to accept S0013. Those payers now need to take J0013 instead. Practices should check that their billing software, fee schedules, and payer setups all swapped S0013 for J0013 before the first claim of the year went out. CMS did not announce a grace period, so claims filed with the old S0013 for dates of service on or after January 1, 2026 risk rejection.
How Do You Bill J0013 Correctly?
Bill J0013 for the drug and pair it with a service code for the visit and monitoring. The number of J0013 units equals the total milligrams of esketamine given. Here is the basic workflow:
- Confirm the dose the provider gave during the session.
- Report J0013 with units equal to the milligrams given.
- Report the matching service code for the office visit and observation (see the next section on G2082 and G2083).
- Send both lines on the same claim for the same date of service.
Worked unit examples:
- A 56 mg session: bill J0013 with 56 units.
- An 84 mg session: bill J0013 with 84 units.
The unit math is simple, but it is also where most claims go wrong. Some billers enter “1” in the units field because they think of one spray device as one unit. That undercounts the dose and triggers a denial or an underpayment. Other billers convert milligrams to milliliters or to device count. Each of those mistakes breaks the 1 mg = 1 unit rule.
How you get the drug changes the claim path. Two models are common:
- Buy-and-bill: the practice buys the Spravato supply, stocks it, and bills J0013 itself along with the service code.
- Specialty pharmacy: the drug comes from a REMS-certified pharmacy. In that model, the pharmacy bills the medical claim for the drug using J0013, and the practice bills its own claim for the administration and observation service. Iowa Medicaid, for example, spells out this split: the certified pharmacy bills J0013 for the drug, and the provider bills the service codes for administration and the post-administration observation.
Confirm which model your payer expects before the session. Billing J0013 after the specialty pharmacy already billed it results in a duplicate claim.
J0013 vs. G2082 and G2083: Which Codes Go Together?
J0013 reports the drug. G2082 and G2083 report the visit, the supervision, and the two-hour observation. You pair the drug code with the right service code based on dose.
G2082 and G2083 are dose-based service codes that CMS built for esketamine sessions. The split between them is the 56 mg line:
- G2082 covers a session with up to 56 mg of esketamine, including two hours of post-administration observation.
- G2083 covers a session with more than 56 mg of esketamine (such as the 84 mg dose), including two hours of post-administration observation.
Both codes carry the same evaluation, supervision, and 120-minute observation requirements. G2083 pays more because it accounts for the larger dose. Picking G2082 when the patient received more than 56 mg is a common denial cause.
| Code | Description | When to Use | Billing Unit |
| J0013 | Esketamine (Spravato), nasal spray | The drug itself, every session | Per 1 mg |
| G2082 | Outpatient visit with supervision and two-hour observation, up to 56 mg | Office session at the 56 mg dose level | Per session |
| G2083 | Outpatient visit with supervision and two-hour observation, more than 56 mg | Office session at the 84 mg dose level | Per session |
| J3490 | Unclassified drug, legacy fallback | Only during a payer transition gap | Per claim |
A practical note on Medicare: the G-code bundle (G2082 or G2083) packages the drug cost into the procedure payment for Medicare patients. For non-Medicare payers that accept the separate drug code, J0013 reports the drug on its own line. Confirm each payer’s rule, because the same session can be coded differently depending on who pays.
Payer-Specific Updates for Spravato J0013 Code
Coverage rules for esketamine differ by payer, even though everyone moved off S0013 on the same date. Here is how the major payers handle J0013 as of mid-2026. Policies change often, so treat this as a starting point and confirm the current version with each payer before you bill.
Medicare
Medicare generally treats J0013 as a non-payable code for the drug itself in most buy-and-bill cases. Instead, Medicare wants the bundled G-codes: G2082 for sessions up to 56 mg and G2083 for sessions above 56 mg. Both bundles fold the drug cost into the procedure payment, so you are not billing J0013 as a separate line for a Medicare patient in most cases. Coverage applies to FDA-approved uses, meaning treatment-resistant depression or major depressive disorder with suicidal thoughts, alongside an oral antidepressant, given in a REMS-certified setting. Check the Local Coverage Determination for your area for the exact rules.
Aetna
Aetna’s coverage policy lists J0013 as the current drug code. Aetna requires prior authorization for Spravato, tied to the same criteria most payers use: prior antidepressant trials that failed, psychiatrist involvement, and administration in a REMS-certified setting with monitoring. Authorizations that were approved under S0013 are often honored until they expire, but renewals need to move to J0013. Some claims also use a separate administration code alongside the drug code.
Cigna
Cigna’s coverage policy updated to J0013 effective January 1, 2026, with S0013 marked as valid only through December 31, 2025. Cigna requires prior authorization and covers Spravato for the same FDA indications, subject to criteria like documented failed antidepressant trials. Cigna’s Medicare Advantage plans still use the G2082/G2083 bundle rather than J0013 on its own. Cigna’s policy also lays out continuation criteria for patients staying on therapy past the first round.
UnitedHealthcare (UHC)
UHC’s drug policy documents list J0013, with J3490 noted as a possible fallback where J0013 has not yet loaded. UHC covers Spravato for treatment-resistant depression when standard criteria are met, including diagnosis confirmation, failed prior trials, use alongside an oral antidepressant, and REMS enrollment. Prior authorization is typically required. Commercial plans are expected to follow the code update, but the safest move is to check the specific plan document before billing.
Medicaid and Other Payers
State Medicaid programs are moving on the same timeline as commercial payers, though the details vary by state. Iowa Medicaid, for instance, required J0013 starting January 1, 2026, and asked practices to update any prior authorizations that were still tied to S0013. Medicare crossover claims in Iowa still route through the G2082/G2083 bundle. Most other commercial payers have adopted or are actively adopting J0013. If a claim denies, contact the payer directly to ask whether a grace period applies or whether they still expect J3490 during their transition.
Billing reminders that apply across payers:
- Always match J0013 units to the exact milligrams given, not the device count.
- For non-Medicare payers billing J0013 separately, the office visit and observation are billed on their own codes.
- Spravato must come from a REMS-certified prescriber, setting, and pharmacy, regardless of payer.
- Drug pricing for J0013 is ASP-based and can shift with each quarterly update, so confirm current rates rather than relying on a fixed number.
- Manufacturer savings programs may lower a patient’s out-of-pocket cost, but they do not change how the practice bills the claim.
What Documentation Supports a J0013 Claim?
A J0013 claim needs a session record that shows the exact dose, the monitoring time, and proof of REMS compliance. Payers tie payment to this chart detail, so missing pieces turn paid sessions into write-offs.
At a minimum, each session record should include:
- The exact dose of esketamine given, which confirms whether the session is G2082 or G2083.
- The start and end time of the two-hour post-administration observation period.
- Vital signs and clinical monitoring notes taken across the observation window.
- Proof that the patient, prescriber, and setting are enrolled in the REMS program.
REMS is the FDA safety requirement for esketamine. Every healthcare setting, prescriber, and patient must be enrolled in the SPRAVATO REMS program before any dose is given or billed. The program exists because esketamine carries risks of sedation, dissociation, and misuse, which is why the two-hour monitored observation is built into the service codes. The billing record and the REMS record need to match.
Many payers also require prior authorization before the session. Verify the patient’s authorization is active and matches the planned dose. An expired or dose-mismatched authorization is a common reason a clean-looking claim still denies.
Two example scenarios show how the documentation maps to the codes:
- Single 56 mg session: chart the 56 mg dose, the two-hour observation start and end times, vitals, and REMS enrollment. Bill J0013 at 56 units plus G2082.
- An 84 mg session: chart the 84 mg dose, the two-hour observation start and end times, vitals, and REMS enrollment. Bill J0013 at 84 units plus G2083.
How Do You Prevent J0013 Claim Denials?
Prevent denials by matching units to milligrams, getting prior authorization, and pairing the drug code with the correct dose-based service code. Most esketamine denials trace back to one of those three failures.
The top denial reasons:
- Unit miscalculation: billing J0013 with the wrong unit count, most often “1” instead of the milligram total.
- Missing or mismatched prior authorization: no active authorization, or one that does not match the dose given.
- Code mismatch: using G2082 for a session over 56 mg, or sending the service code without the drug code (or the reverse) when the payer expects both.
Prior authorization best practices:
- Verify the authorization is active before each session, not just at the start of care.
- Confirm the authorized dose matches the planned dose.
- Track renewal dates so a lapse does not stop a scheduled session.
A pre-submission checklist:
- Units on J0013 equal the milligrams given.
- The service code (G2082 or G2083) matches the dose.
- Prior authorization is active and dose-matched.
- Place of service matches the site of care.
- The chart shows dose, two-hour observation times, vitals, and REMS enrollment.
Final Words
S0013 became J0013 on January 1, 2026. The correct approach is to bill J0013 for the drug at 1 mg per unit and pair it with G2082 or G2083 for the visit and observation. Match units to milligrams, confirm prior authorization and REMS enrollment, and use the dose-based G-code that fits the session. Medicare, Aetna, Cigna, UHC, and Medicaid programs each finalized this switch on their own schedule, so confirm the current policy for the specific plan before you submit a claim.
Accuracy matters most right now because many payers are still transitioning from S0013 to J0013. A claim filed with the retired code, the wrong unit count, or a mismatched service code can stall during this adoption window. Confirm each payer’s current setup before you submit.
Need help with J0013 and Spravato billing? FC Billing delivers end-to-end Spravato billing solutions, including prior authorization support, accurate coding, claims submission, denial management, and ongoing reimbursement optimization to help treatment centers maximize collections and stay compliant.
